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Abstract: Community-acquired pneumonia (CAP) is among the most commonly prevailing acute 
infections in children that may require hospitalization. Inconsistencies among suggested care and 
actual management practices are usually observed, which raises the need to assess local clinical 
practices. The current study was conducted to evaluate pediatricians’ compliance with the standard 
clinical practice guidelines and their antibiotic-prescribing behavior for the management of CAP in 
children. Methods: A descriptive cross-sectional study was conducted using a self-administered 
questionnaire; which was provided to pediatricians by the researchers. Statistical analysis was 
performed with SPSS 25 Statistics; χ2 tests (or Fisher-exact tests) with the p-value set at < 0.05 as the 
threshold for statistical significance. Results: The overall response rate was 59.2%. Male respondents 
were (n = 101; 42.6%), and the respondents (n = 163; 68.7%) were under 30 years of age. Amoxicillin 
(n = 122; 51.5%) was considered as the most commonly used first-line treatment for non-severe 
pneumonia, whereas a smaller proportion (n = 81; 34.2%) of respondents selected amoxicillin–
clavulanate. Likewise, amoxicillin (n = 100; 42.2%) was the most popular choice for non-severe 
pneumonia in hospitalized children; however, if children had used antibiotics earlier to admission, 
respondents showed an inclination to prescribe a macrolide (n = 95; 40.0%) or second-generation 
cephalosporin (n = 90; 37.9%). More than 90% responded that children <6 months old with suspected 
bacterial CAP will probably receive better therapeutic care by hospitalization. Restricting exposure 
to the antibiotic as much as possible (n = 71; 29.9%), improving antibiotic prescribing (n = 59; 24.8%), 
and using the appropriate dose of antimicrobials (n = 29; 12.2%) were considered the major factors 
by the respondents to reduce antimicrobials resistance. Conclusions: The selection of antibiotics 
and diagnostic approach was as per the recommendations, but indication, duration of treatment, 
and hospitalization still can be further improved. 
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1. Introduction 
Community-acquired pneumonia (CAP) is a commonly prevailing lower respiratory 
tract (LRT) infection that remains one of the major reason for early pediatric mortality, 
particularly in resource-limited countries [1,2]. A child having rapid, shallow breathing 
(tachypnea) and chest indrawing is considered to have “pneumonia”. CAP refers to 
pneumonia that is developed in a child in a community or outside of the healthcare system 
[2]. CAP is among the most well-known respiratory diseases requiring pediatric 
hospitalization. Inappropriate management of CAP patients or the delayed admission of 
patients to the intensive care unit (ICU) is revealed to be accompanied with augmented 
mortalities, and it is critical for general practitioners (GPs) to detect relevant patients 
suffering from severe pneumonia as quickly as possible [3]. The United States alone 
reports an incidence of 634 cases per 100,000 persons, leading to almost 1.5 million 
hospitalizations per annum [4]. However, in Pakistan, there are a lack of data on burden 
of pneumonia in terms of morbidity and mortality. 
The World Health Organization (WHO) has defined the health profile of Pakistan by 
increase in maternal mortality, higher population growth rate, higher infant and child 
mortality, and increased disease burden. Optimal management of CAP is a challenging 
task particularly in resource-limiting countries such as Pakistan, which is lacking 
advanced healthcare facilities. Although the population in Pakistan had inadequate access 
to appropriate healthcare facilities, the number of medical graduates had been rising with 
a dramatic increase seen from 1300 in 1977 to 3800 in 1988 [5]. Presently, the doctor-to-
patient ratio is 1:1300 in Pakistan, which is bigger than a baseline of 1:60,000 in 1947 [5]. 
Even with doctors graduating in such large figures, the shortage is still not addressed, and 
there is an irregular distribution of healthcare services among urban and rural regions [6]. 
In addition, the empiric use of antibiotics for acute respiratory infections is one of the 
leading factors of antibiotic misuse in developing countries. Inadequate evidence on 
potential pathogens and the local profile of bacterial drug resistance usually leads to 
poorly directed and needless antibiotic use [4]. Inadequate contemplation of the risks 
accompanying the unwanted use of antibiotics is a matter of serious concern. Boosting the 
rational use of antibiotics is a global priority, especially in Asian countries, where the non-
prescription accessibility of antibiotics is commonly unobstructed [5]. The PIDS/IDSA 
recommendations for the management of CAP were generated to support clinicians in the 
management of CAP in children and to homogenize medicinal care [6]. These guidelines 
aim to decrease morbidity and mortality rates in children with CAP by improving the 
clinical care of these patients. However, there are some inconsistencies between actual 
management practices and recommendations, leading to the misuse of antibiotics, an 
increase in resistance rates of community-acquired pathogens, and extensive duration of 
hospitalizations [7]. 
Physicians contribute significantly to the management of CAP by immediate 
diagnosis, proper antibiotic regime, and by recognizing risk factors. Discrepancies among 
suggested care and actual management strategies by the physicians are usually observed, 
which raises the need to assess our local clinical practices. In Pakistan, inadequate 
exploration has been conducted on CAP, and the current study was the first one 
conducted with the aim to evaluate pediatricians’ compliance to the standard clinical 
practice guidelines and their antibiotic-prescribing behavior for the management of CAP 
in children. 
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2. Materials and Methods 
2.1. Study Design 
A descriptive cross-sectional study was conducted during the period of two months 
between December 2020 and January 2021 using a self-administered questionnaire, which 
was provided to pediatricians by the researchers. 
2.2. Study Population and Sample Size Calculation 
The pediatricians and physicians—particularly those working in pediatric wards—
in 4 public and 2 private tertiary care hospitals of Karachi were considered as the target 
population of the study. Karachi is the biggest city in Pakistan and the twelfth largest city 
in the world. It is the capital of the Sindh province of Pakistan. Respondents were selected 
by the convenience sampling technique. The size of the study sample was calculated with 
the Raosoft sample size calculator (Raosoft Inc.®, Seattle, WA, USA) [8] by using the 
following formula: 
x = Z(c/100)2 r(100 − r)  
n = N x/((N−1)E2 + x)  
E = Sqrt[(N − n)x/n(N − 1)]  
where r is the fraction of responses, N is the population size, n is the sample size, E is the 
confidence interval, c is the confidence level, and Z(c/100) is the critical value for the 
confidence level. 
2.3. Inclusion and Exclusion Criteria 
The following respondents were included in the study: 
a. pediatricians or physicians working in pediatric settings of the hospital, including 
neonatal intensive care unit (NICU)/neonatal care, pediatric intensive care (PIC), 
pulmonology, emergency medicine, infectious diseases, outpatient clinics, general 
pediatrics, and the private pediatric clinics and 
b. if they agreed to participate in the study. When potential respondents were 
approached, they were briefed about the objectives of the study and the time required 
to complete the survey. They were informed that no incentives will be presented to 
them for their contribution and that participation is voluntary. 
2.4. Study Instrument 
A 42-item questionnaire was developed, based on a comprehensive review of the 
literature [9], the clinical practice recommendations by the Pediatric Infectious Diseases 
Society (PIDS) [10], and the Infectious Diseases Society of America (IDSA) [6] under the 
guidance of the opinions of an expert panel, including three senior physicians and two 
infectious disease specialists. On concluding the content validity, the questionnaire was 
pre-tested in a small sample of physicians (n = 30), to evaluate the clarity and transparency 
of the individual questionnaire items (face validity). The Hoyt method λ 3 {\displaystyle 
\lambda _{3}} reliability scale was applied, and the value of reliability was found to be 
0.783. Then, the questionnaires were circulated via email or direct correspondence among 
the respondents, after apprising their motivation to participate in this research. The 
questionnaire has 4 questions related to demographic characteristics, and 21 questions 
addressed their agreement with the recommended clinical practice guidelines. The 
questionnaire includes 17 items to analyze the respondents’ adherence toward the 
guidelines in their practice using a 5-point Likert-scale ranging from 1 = strongly disagree 
to 5 = strongly agree. Additionally, the questions were included regarding the 
respondents’ preferences and their practices for antibiotic treatment of children with CAP, 
indications and duration of CAP hospitalization, IV antibiotic use, and ICU admission. 
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2.5. Ethical Considerations 
The study was conducted agreeing with the recommendations of the Declaration of 
Helsinki and approved by the Institutional Review Board of Liaquat College of Medicine 
and Dentistry, Darul Sehat Hospital, Karachi, Pakistan (Reference No. 
DSH/IRB/2021/0028). The written consent was taken from the respondents before the 
study. 
2.6. Data Analysis 
The data were evaluated by Statistical Package for the Social Sciences® (SPSS) for 
Windows version 25.0 (IBM Corporation, Armonk, NY, USA). All categorical variables 
were described using frequencies (n) and proportions (%). Data were statistically 
analyzed with χ2 tests (or Fisher-exact tests) with the p-value set at < 0.05 as the threshold 
for statistical significance. 
3. Results 
3.1. Demographic Characteristics 
In this study, 400 survey forms were distributed among the pediatricians and 
physicians working in pediatric wards belonging to different tertiary care hospitals in 
Karachi. Two hundred and thirty-seven (n = 237) pediatricians and physicians consented 
to participate in the research. The response rate observed was 59.2%. Out of the 
respondents, male respondents were in the minority (n = 101; 42.6%), while (n = 163; 68.7%) 
of respondents were under 30 years of age (Table 1). The majority of the respondents (n = 
151; 63.7%) were serving in public hospitals, while a little over half (n = 123; 51.8%) of 
respondents had 1-5 years of clinical experience. The respondents (n = 225; 94.9%) 
routinely prescribe antibiotics to the patients. However, the response was significantly 
associated with the age  
(p = 0.014), type of working hospital (p = 0.02), and experience (p = 0.001) of respondents. 
More than two-thirds (n = 160; 67.5%) of respondents stated that they would not treat 
children with antibiotics if a viral LRT infection is presumed. The majority of the 
respondents (n = 180; 75.9%) preferred the oral route of antibiotic administration in 
children compared to intravenous (IV) administration. 
Table 1. Demographic characteristics of respondents. 
Characteristics Frequency (n; %) 
Gender 
Male 101 (42.6) 
Female 136 (57.3) 
Age 
<30 years 163 (68.7) 
30–39 years 69 (29.1) 
40–49 years 5 (2.1) 
Type of Working Hospital 
Private 86 (36.2) 
Public sector 151 (63.7) 
Experience 
< 1 year 62 (26.1) 
1–5 years 123 (51.8) 
5–10 years 47 (19.8) 
10–15 years 4 (1.6) 
>15 years 1 (0.4) 
Use antibiotics extensively in clinical practice 
Yes 225 (94.9) 
No 12 (5.0) 
Preferable route of antibiotic administration 
Oral  180 (75.9) 
Intravenous (IV) 45 (18.9) 
Intramuscular (IM) 12 (5.0) 
Would you manage a child with a  
presumed viral LRT infection with antibiotics? 
Yes 77 (32.4) 
No 160 (67.5) 
Do you know the adverse effects associated with the use of antibiotics in children? 
Yes 231 (97.4) 
No 5 (2.1) 
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3.2. Respondents’ Preferences for Antibiotic Treatment in a CAP Child 
Table 2 summarizes the respondents’ preferences for antibiotic treatment in a CAP 
child. Amoxicillin (n = 122; 51.5%) was considered as the most preferred first-line 
treatment for non-severe pneumonia, whereas other respondents (n = 81; 34.2%) opted for 
amoxicillin–clavulanate. Likewise, amoxicillin (n = 100; 42.2%) was the most popular 
choice for non-severe pneumonia in hospitalized children; however, if children had 
previously received antibiotics prior to admission, respondents showed an inclination to 
instead prescribe a macrolide agent (n = 95; 40.0%) or a second-generation cephalosporin 
(n = 90; 37.9%). The response varies with the type of working hospital of respondents; 
those who were working in a private setting were more likely to use macrolides (p = 0.011). 
In a child hospitalized with severe CAP, a third-generation cephalosporin (ceftriaxone or 
cefotaxime) was generally chosen by respondents (n = 155; 65.4%) if a child had not used 
antibiotics earlier to admission, together with gentamicin as an add-on medication. The 
response rate varies with the experience of respondents (p = 0.021). Likewise, a third-
generation cephalosporin (ceftriaxone or cefotaxime) was selected by the majority of the 
respondents (n = 184; 77.6%) if a child had received antibiotics prior to hospital 
admission. 
Table 2. Respondents’ preferences for antibiotic treatment in a CAP child. 
Scenario 
Antibiotic Choice   
First Priority, n (%) Second Priority, n (%) Third Priority, n (%) Other Priorities, n (%) 
Non-Severe Pneumonia 
Outpatient 
Amoxicillin Amoxicillin clavulanate Macrolide  
122 (51.5) 81 (34.2) 25 (10.5) 9 (3.7) 
Inpatient  Non-Severe Pneumonia   
Without previous use of 
antibiotic 
Amoxicillin Amoxicillin clavulanate Macrolide  
100 (42.2) 93 (39.2) 33 (13.9) 11 (4.6) 




Amoxicillin clavulanate  
95 (40.0) 90 (37.9) 44(18.5) 8 (3.3) 
  Severe Pneumonia  
Without previous use of 
antibiotic 
Cephalosporin (3rd generation) Ampicillin or penicillin G Gentamycin  
155 (65.4) 62 (26.1) 11 (4.6) 9 (3.7) 
With previous use of antibiotic 
Cephalosporin (3rd generation) Ampicillin or penicillin G Gentamycin  
184 (77.6) 26 (11.0) 15 (6.3) 12 (5.0) 
3.3. Respondents’ Practice for the Duration of CAP Hospitalization and IV Antibiotic Use 
Table 3 summarizes respondents’ self-reported existing practices, depicting the 
average length of CAP hospitalization and the administration of IV antibiotics. The 
respondents specified that they would discharge a child with non-severe CAP within 5 
days  
(n = 143; 60.5%) but keep a child with severe CAP hospitalized for 6–7 days (n = 115; 
48.5%). Older respondents were more likely to keep a child hospitalized if they are 
affected by severe pneumonia for 8–10 days (p = 0.016). In case of a child with severe 
pneumonia, more than half of respondents (n = 128; 54.0%) provided IV antibiotics for 6–
7 days, while only three respondents indicated an inclination for switching to oral 
antibiotics. More than 90% stated that blood cultures should normally not be taken in a 
completely vaccinated child with CAP, receiving treatment in an outpatient setting. 
Around 92% of respondents said that specific and sensitive tests for the prompt 
identification of influenza and other respiratory tract viruses must be conducted for the 
assessment of a CAP child. 
The national guidelines (n = 180; 75.9%) followed by a local experts’ opinion (n = 29; 
12.2%) were the more persuasive factors for respondents’ antibiotic prescribing behavior. 
(see Table 4). Clinical assessment (n = 197; 83.1%) followed by a complete course of IV 
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antibiotics (n = 19; 8.0%) were the major factors influencing the respondents’ decision to 
discharge a child from the hospital. Around 90% of the respondents stated that a 
hospitalized CAP child could be discharged safely when they show complete 
improvement in CAP symptoms, including reduced fever for at least 12–24 h, the normal 
activity level, a healthy appetite, stable mental status, and consistent pulse oximetry 
measurements >90% in ambient air for at least 12–24 h. 
Table 3. Respondents’ practice for the duration of CAP hospitalization and intravenous antibiotic use. 
Length of Hospitalization and Intravenous Use of Antibiotic No. of Days Frequency (n; %) 
Duration of hospital stay in non-severe pneumonia 
<3 days 66 (27.8) 
3–5 days 143 (60.5) 
6–7 days 21 (8.8) 
8–10 days 7 (2.9) 
Duration of hospital stay in severe pneumonia 
<5 days 14 (5.9) 
6–7 days 115 (48.5) 
8–10 days 73 (30.8) 
11–14 days 35 (14.6) 
IV antibiotics to a child with severe pneumonia 
<3 days 1 (0.4) 
3–5 days 82 (34.5) 
6–7 days 128 (54.0) 
8–10 days 26 (10.9) 
Table 4. Elements that influenced respondents’ antibiotic prescribing behavior and decision to discharge a CAP child. 
Decision 
Strength of Influencing Factor 
First Second Third   
Antibiotic prescribing  
behavior 
National guidelines Local Expert opinion Best available drug Other factors 
180 (75.9) 29 (12.2) 21 (8.9) 7 (2.9) 
Hospital discharge 
Clinical Assessment Complete IV Antibiotic course Parental request Other factors 
197 (83.1) 19 (8.0) 9 (3.8) 12 (5.0) 
3.4. Respondents’ Perceived Indications for CAP Hospitalization, Antibiotic Therapy, and ICU 
Admission 
Table 5 showed the respondents’ perceived indications for CAP hospitalization and 
the administration of antibiotic therapy for CAP. Almost all the respondents stated that a 
moderate-to-severe CAP child must be hospitalized to achieve adequate care; however, 
more experienced respondents were more likely to believe that hospitalization is 
necessary to provide sufficient therapeutic care to the patient (p = 0.026). More than 90% 
opined that children of age <6 months with suspected bacterial CAP may get better 
therapeutic care by hospitalization. The majority (n = 210; 88.6%) of the physicians 
responded that amoxicillin must be used as the first choice for fully immunized infants 
and toddlers who were previously healthy, with minor-to-moderate bacterial CAP. The 
respondents  
(n = 190; 80.1%) stated that vancomycin or clindamycin (depending on susceptibility data) 
must be given along with the β-lactam therapy, if clinical presentation indicates a 
Staphylococcus aureus infection. More than 75% of respondents agreed that amoxicillin 
appropriately provides coverage for Streptococcus pneumoniae, and influenza antiviral 
treatment should be directed as soon as possible to a child with moderate-to-severe CAP 
consistent with an influenza virus infection. More than 90% (n = 215) of respondents 
indicated the need for ICU admission if a child needs invasive ventilation, having altered 
mental status and depicting other altered clinical, radiological, and laboratory findings. 
The respondents with the higher age (p = 0.037), greater experience (p = 0.021), and 
working in private hospital (p = 0.002) showed better knowledge regarding the child’s 
need for ICU admission. 
Healthcare 2021, 9, 701 7 of 13 
 
 










Child or Infant with CAP who Must Be Hospitalized 
A child with moderate to severe CAP must be hospitalized for better clinical care 235 (99.1) 0 (0) 2 (0.8) 
Children of age <6 months with suspected bacterial CAP are likely to get better therapeutic care by hospitalization 214 (90.2) 20 (8.4) 3 (1.2) 
Children with suspected CAP caused by an increased virulence pathogen, for instance, community-associated methicillin-resistant 
Staphylococcus aureus (CA-MRSA)  204 (86.0) 19 (8.0) 9 (3.7) 
Children who lack vigilant observation at home or incapable of following the recommended therapy  192 (81.0) 27 (11.3) 13 (5.4) 
Anti-Infective Treatment 
Antibiotic is not compulsory for a preschool-aged CAP child, as commonly, the infection is caused by virus.  172 (72.6) 31 (13.1) 34 (14.3) 
Amoxicillin must be used as the first choice for immunized infants and toddlers who were previously healthy and have minor to  
moderate bacterial CAP. 
210 (88.6) 17 (7.1) 9 (3.7) 
Amoxicillin provides suitable coverage for Streptococcus pneumoniae. 185 (78.0) 29 (12.2) 23 (9.7) 
Macrolide antibiotics must be given for the management of a child with CAP caused by atypical pathogens in an outpatient setting.  185 (78.0) 38 (16.0) 13 (5.4) 
Influenza antiviral treatment should be directed as prompt as possible to a child with moderate to severe CAP due to the  
influenza virus. 
179 (75.5) 44 (18.5) 14 (5.9) 
Ampicillin or penicillin G should be given to the appropriately immunized child admitted in hospital with CAP due to  
S. pneumoniae. 
168 (70.8) 40 (16.8) 29 (12.2) 
Empiric treatment with a third-generation parenteral cephalosporin should be given for hospitalized infant or child who is not completely 
vaccinated, or for an infant or child with a life-threatening condition 
186 (78.4) 43 (18.1) 8 (3.3) 
Macrolide along with a β-lactam antibiotic must be given to the hospitalized child for whom Chlamydophila pneumoniae and  
Mycoplsma pneumoniae are major concerns. 
166 (70.1) 51 (21.5) 15 (6.3) 
Vancomycin or clindamycin should be provided along with β-lactam treatment if the infection is due to Staphylococcus aureus. 190 (80.1) 36 (15.1) 11 (4.6) 
A child on appropriate therapy must reveal indications of improvement within 48–72 h. 182 (76.7) 33 (13.9) 22 (9.2) 
A child whose illness worsens after admission or who did not show any progress within 48–72 h needs additional examination. 206 (86.9) 28 (11.8) 3 (1.2) 
Outpatient parenteral antibiotic therapy should be given only to those children who do need nursing attention in an acute care setting; however, 
their ongoing parenteral treatment is necessary. 178 (75.1) 37 (15.6) 17 (7.1) 
Switching to oral therapy whenever possible is preferential to parenteral outpatient treatment. 183 (77.2) 41 (17.2) 13 (5.4) 
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3.5. Respondents’ Perceived ways of Reducing Antimicrobials Resistance through Appropriate 
Management 
Restricting exposure to the antibiotic as much as possible (n = 71; 29.9%), improving 
antibiotic prescribing (n = 59; 24.8%), and using the appropriate dose of antimicrobials  
(n = 29; 12.2%) were considered the major factors by the respondents to reduce 
antimicrobials resistance (Figure 1). The majority of respondents (48.1%) opined that an 
open lung biopsy should be conducted for Gram-stain and culture in a child not showing 
any improvement within 48–72 h of treatment (Figure 2). More than 90% stated that all 
children and adolescents should be vaccinated once a year for the influenza virus to 
prevent the development of pediatric CAP. 
 
Figure 1. Respondents’ perceived ways of reducing antimicrobials resistance. 
 
Figure 2. Respondents’ perceived management of the child not responding to treatment. 
Improving antibiotic prescribing practice
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Imaging evaluation to assess the extent and progression of
the pneumonic or parapneumonic process
Further investigation to identify whether the original
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A percutaneous lung aspirate should be obtained for Gram
stain and culture












The current study was executed to investigate the physicians’ compliance to the 
standard clinical practice recommendations for managing pediatric CAP. The response 
rate of the current study was 59.2%, which may be considered appropriate in light of the 
literature findings. A similar lower response rate of physicians was observed in another 
study [11]. Studies have shown that the response rates are usually lower for physicians as 
compared to general community surveys, which may be due to physicians’ tough work 
schedules and an increase in the frequency of being approached for studies [12,13]. 
In the present study, the majority of the respondents commonly prescribe antibiotics 
to the patients. Therefore, it is significant to evaluate the physicians’ practice of using 
antibiotics, along with factors influencing their prescribing behavior to develop future 
approaches to increase the rational use of antibiotics [14]. However, the majority of 
respondents stated not to give an antibiotic to a child with a presumed viral LRT infection; 
the principal reason for this was that they knew the adverse effects accompanying the use 
of antibiotics in children. The misuse of antibiotics is related to preventable adverse drug 
effects and greater healthcare expenses and leads to the increasing global crisis of 
antimicrobial resistance [14]. In addition, while some novel agents have been authorized 
recently for the use of treating CAP (delafloxacin, lefamulin), nevertheless, none of these 
agents may be used in the pediatric population [14]. The healthcare professionals must 
contemplate their responsibility in educating the community to inhibit the irrational usage 
of antibiotics. In this study, the majority of the respondents preferred the oral route of 
antibiotics in children, which is parallel to the findings of another study in which the 
physicians favored using oral over intravenous or intramuscular antibiotic injections [9]. 
The PIDS/IDSA guiding principles publication in 2011 were set to permit improved 
clinical effects and decrease management discrepancies [6]; several studies inspected 
pediatricians’ adherence to them. In our study, an inclination for broad-spectrum 
antibiotics was observed even though using antibiotics such as amoxicillin–clavulanate or 
later-generation cephalosporin administered empirically do not propose any benefit over 
amoxicillin [15]. Among the surveyed respondents, third-generation cephalosporin was 
preferred for a child with severe CAP regardless of preceding exposure to the first-line 
therapy with antibiotic. Another study reported that treatment with the narrow-spectrum 
antibiotics was not less significant to broad-spectrum antibiotics in all measurable clinical 
outcomes together with the length of stay and duration of fever [16]. Many pediatricians 
stated that a cephalosporin must be used if a child does not show an improvement to first-
line therapy with oral amoxicillin or IV ampicillin for non-severe and severe pneumonia, 
respectively. Younger respondents usually follow the local practices, even though they do 
not conform with standard pediatric CAP management recommendations [17]. It is 
observed that physicians considered broader-spectrum or novel antibiotics as more 
effective, which is an imprint that is frequently reinvigorated by promotion from 
pharmaceutical organizations [18]. The national guidelines followed by local expert 
opinion were the respondents’ reported persuasive factors for antibiotic prescribing 
behavior in the present study. At times, the parent beliefs, along with their expectations 
and demands, contribute significantly to inappropriate antibiotic-prescribing by 
physicians. It is observed that due to the self-perceived seriousness of the infection, 
sometimes, the parents who get more anxious about their child’s disease are likewise more 
inclined to use antibiotics. Patients who expect to receive antibiotics were prescribed 
antibiotics more frequently comparing to those who were not expecting them. For that 
reason, the inappropriate prescribing and promotion of antibiotics in the community 
might be due to both the patients’ demands and the profit interest of the healthcare 
providers, which may jeopardize the healthcare needs and safety of the patients. The 
parallel findings were reported by another study, in which some physicians stated that 
pressure from patient’s family members persuaded them to prescribe antibiotics [9]. This 
finding was reinforced by a Hungarian study, where 25.0% of the respondents admitted 
that the temperament of patients (or parents) significantly influences their antibiotic-
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prescribing practices; additionally, 69.2% think that much more effort should be put into 
providing the point-of-care tests (POCT) to help physicians to better assess the presence 
of an indication for antibiotic therapy [19]. In the current study, around 92% stated that 
specific and sensitive examinations for the prompt identification of influenza and other 
respiratory tract viruses must be conducted in the assessment of a child having CAP. It is 
evident that enhanced timely information of likely pathogens at the initial stage of 
therapeutic care and the probable susceptibility of bacterial pathogens might support in 
guiding antibiotic-prescribing choices and consequently prevent avoidable antibiotic use 
[19]. More than 90% of respondents in the current study stated that blood cultures should 
normally not be conducted in a completely vaccinated child with CAP getting treatment 
in the outpatient setting. However, the blood cultures should be taken in a child who 
needed hospitalization for presumed moderate-to-severe bacterial CAP, specifically those 
with the complex clinical presentations. It is neither easy nor cost-effective to detect 
microbial etiology in all pediatric patients presented with LRT infections in primary care 
due to sampling challenges, inadequate diagnostic facilities, and the limited clinical 
effectiveness of getting a result once empirical treatment choice has been made [20]. 
The current study revealed the inclination of respondents to provide IV antibiotics 
for 6–7 days in a child with severe pneumonia and less preference for switching to oral 
antibiotics. As per the American CAP treatment recommendations, there is no suggested 
rigid length of treatment; however, a 10-day antibiotic course is considered as adequate 
and could be protracted when there is a probability of certain pathogens or when 
radiological or clinical conditions get worse during a hospital stay [6]. The WHO 
recommends a shorter antibiotic course for children aged <5 years [21]. Numerous studies 
on the management of pediatric pneumonia revealed no major difference among short 
and long-duration courses neither in the measurement of clinical outcomes nor in 
management failure or recurring rates [22–25]. In the current study, more than 90% opined 
that a child of age <6 months with presumed bacterial CAP could get better therapeutic 
care during hospitalization. The clinical assessment followed by a complete IV antibiotic 
course were the major factors that influenced respondents’ decision to discharge a child 
from the hospital in the current study. Although physicians specified that they would 
generally discharge a child with non-severe pneumonia within 5 days, management with 
oral antibiotics (if necessary) at home has been revealed to be similarly effective [23]. The 
commonly practiced duration of hospitalization by the respondents for severe pneumonia 
was 6–7 days, which corresponds with a retrospective study where the average stay at the 
hospital was 7–6 days for acute respiratory infection [17]. Regardless of a common 
predilection for oral antibiotics, the respondents showed a willingness to complete a 
complete course of IV antibiotics in children with severe pneumonia. The significance of 
a timely oral switching strategy, which decreases hospital stay, secondary health 
problems, and other healthcare expenses, has been confirmed in several studies [24,25]. 
Yet, extended hospitalization for the IV antibiotics administration remains a general 
practice in the Asian region countries. By reducing needless hospitalization for IV 
antibiotics, major health expenses may be saved [26]; however, none of the study 
respondents confessed to generating revenue from prescribing antibiotics. In some 
countries, drug prescriptions normally increase a doctor’s earnings, and the exclusion of 
these profitable inducements accompanied by improved regulation can significantly 
decrease the misuse [27]. China has declared a strategy to preclude hospitals and 
physicians from earning from unnecessary use of antibiotics [28]. Almost all respondents 
comprehended that improved guidelines are necessary to fix the needless use of 
antibiotics in Pakistan; however, antibiotics remain continually available over the counter, 
and no limitations on their accessibility have been proclaimed to date. The problem of 
precisely differentiating viral and bacterial pneumonia is a key driver of the appropriate 
use of antibiotics. Respondents opined that the availability of enhanced microbiological 
facilities would decrease antibiotics use, and parallel findings were reported by another 
study [29]; they have indicated that despite a known respiratory virus, some respondents 
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would still prescribe antibiotics due to bacterial co-infection concerns. In the current 
study, limiting exposure to an antibiotic was considered to be the most beneficial 
approach of reducing antimicrobial resistance. Other studies reported antibiotic 
stewardship programs, access to better microbiology services, and rapid influenza tests 
as the significant factors to decrease antibiotic prescriptions [30,31]. Another study 
revealed that a C-reactive protein test can progressively reduce avoidable antibiotic use 
[32]. However, it is certain that due to the lack of local surveillance data to provide 
evidence on drug resistance patterns of commonly prevailing respiratory pathogens, 
physicians are more likely to overuse empirical broad-spectrum antibiotics [33]. 
This is the first study conducted to formally assess pediatrician compliance toward 
the clinical practice recommendations for managing a child affected by CAP in Pakistan. 
However, the current study is limited, as it has only measured respondents’ self-perceived 
existing practices and has been directed to physicians working in the city of Karachi. The 
majority of respondents were less than 30 years of age and so were less experienced. The 
study was conducted on a limited number of pediatricians of Karachi, and the outcomes 
could not be generalized for the entire pediatricians of Pakistan or in other parts of the 
world. Due to the hectic clinical schedule, many respondents may have rushed to 
complete their surveys and spent a nominal amount of time in profound consideration. 
However, this prompt comprehensive response might have greater accurateness as the 
impulsiveness of replies must have condensed social desirability biases. Despite these 
limitations, it may be assumed that the responses may be comparable to the observed 
physicians’ practices in other studies. 
5. Conclusions 
The outcomes revealed that the selection of antibiotics and diagnostic approach was 
as per the recommendations, but indication, duration of treatment, and hospitalization 
still could be further improved. The respondents knew that there is a need to decrease 
preventable antibiotic use and to encourage timely oral switch as applicable. They 
emphasize the need for antibiotic stewardship, better drug regulation, and the availability 
of advanced microbiological services throughout Pakistan. The results have potentially 
prepared a platform to identify the discrepancies between actual management practices 
and standard recommendations that might be useful for local health authorities in 
developing future strategies to homogenize and provide optimum patient care. 
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